GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes

Are glucagon-like peptide-1 receptor agonists (GLP-1 RAs) associated with cardiovascular and kidney outcomes in patients with type 2 diabetes, and do these associations differ by body mass index (BMI)?In this cohort study of 97 156 adults with type 2 diabetes, use of GLP-1 RAs was associated with significantly lower risks of major adverse cardiovascular events, cardiovascular death, and hospitalization for heart failure among patients with BMI of 25 or greater. Kidney benefits associated with GLP-1 RAs were consistent across BMI categories.These findings suggest that cardiovascular benefits of GLP-1 RAs may be modified by BMI, while kidney benefits were consistent regardless of BMI, supporting individualized treatment decisions in type 2 diabetes care.

Corresponding Author: Ming-Lung Tsai, MD, Division of Cardiology, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, No. 6, Sec. 2, Jincheng Road, TuCheng Dist. 236, New Taipei City, Taiwan (mltsai.cgmh@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.